Track market-moving stories before they get noisy

The market expects AbbVie (ABBV - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The earnings report, which is expected to be released on October 30, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis drugmaker is expected to post quarterly earnings of $3.79 per share in its upcoming report, which represents a year-over-year change of +103.8%.

Revenues are expected to be $17.37 billion, up 10.1% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 1.35% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for AbbVie?For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.26%.

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that AbbVie will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that AbbVie would post earnings of $3.64 per share when it actually produced earnings of $3.65, delivering a surprise of +0.27%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

AbbVie doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAnother stock from the Zacks Large Cap Pharmaceuticals industry, Eli Lilly (LLY - Free Report) , is soon expected to post earnings of $5.38 per share for the quarter ended September 2026. This estimate indicates a year-over-year change of -23.4%. Revenues for the quarter are expected to be $22.11 billion, up 25.6% from the year-ago quarter.

The consensus EPS estimate for Lilly has been revised 0.1% higher over the last 30 days to the current level. However, an equal Most Accurate Estimate has resulted in an Earnings ESP of 0.00%.

This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that Lilly will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Palantir sits within striking distance of a bold year-end target, but a single earnings report on November 2 could either validate the bull case or send shares tumbling toward a very different destination.

Palantir Technologies (NASDAQ:PLTR | PLTR Price Prediction) closed at $196.19 on October 22, 2026. That is just below the $202.50 year-end target 24/7 Wall St. set in its earlier Palantir price prediction. In Friday premarket trading at $195.31, shares were up 9.9% year to date, up 11.3% over one year, and down 2.6% over the past week. Over the past 52 weeks, the stock has traded between $106.37 and $212.94.

Metric
Value

Current Price (Oct. 22 close)
$196.19

Price Target from 24/7 Wall St.
$211.98

Upside
8.1%

Model Rating
Buy

Model Confidence
0.9 (high)

Scoring the Original Thesis Against Fresh Data
The earlier call rested on three pillars:

Government contracts
Commercial AI adoption
Valuation

Government contracts have held up: second-quarter U.S. government revenue reached $809 million, up 90% year over year. Commercial AI adoption has outperformed. U.S. commercial revenue rose 149% to $764 million, net dollar retention climbed to 157%, and U.S. commercial customers grew 35% to 653.

Valuation is where the thesis took damage. The stock fell from $177.07 in mid-January to $133.02 by mid-February and stayed near that level until the August 3 report. Even after that drawdown, Palantir trades at 174 times trailing earnings and 85 times forward earnings.

How the Model Gets to $211.98
The 24/7 Wall St. price target combines three inputs: a trailing P/E value of $196.19, a forward P/E value of $172.19, and the analyst target. The forward input carries 0.5 of the weight, and the blend comes to $187.26. A proprietary factor of 1.132 then raises that figure. It credits technology-sector momentum and 215.4% earnings growth, and it is muted by a beta of 1.602, cautious retail sentiment, and a mega-cap adjustment.

The one-year bull case reaches $226.34, and the downside scenario falls to $177.11. Wall Street leans bullish, with a consensus target of $206.62.

November 2 Decides Whether the Target Holds
Palantir reports third-quarter results on Monday, November 2, after the close. Management guided to $2.160 billion to $2.164 billion in revenue and full-year sales of $8.150 billion to $8.158 billion. That full-year range implies U.S. commercial revenue above $3.424 billion. CEO Alex Karp has set a high bar: “I am driving the business to grow at a rate equal to or above what we have in U.S. commercial for the next 18 months.”

Management noted a Q3 cost ramp tied to new hires. Stock-based compensation reached $265 million last quarter, and international commercial revenue grew only 26%. Bulls point out that the extra spending funds Palantir’s Artificial Intelligence Platform (AIP) and sovereign AI capacity, while free cash flow still rose 130%. At this multiple, however, a guidance raise smaller than investors expect could drive shares toward the downside scenario.

Palantir Outgrows Snowflake but Costs More
Snowflake (NYSE:SNOW) is a useful comparison because it competes for the same enterprise data and AI budgets. Its latest quarterly revenue grew 35.1%, but it remains GAAP unprofitable.

Company
Latest Quarter Revenue Growth
Price/Free Cash Flow

Palantir
92.8%
214.88

Snowflake
35.1%
98.82

Palantir trades at roughly twice Snowflake’s cash-flow multiple, but it grows much faster and earns a GAAP profit. Next to Snowflake, the 24/7 Wall St. price target looks reasonable.

Verdict: $202.50 Remains in Reach
The prior $202.50 year-end target looks reachable. The model’s own base-case path shows $202.38 by late November. On Polymarket, traders put the odds that the stock touches $204 in October at 0.53. On November 2, the number to watch is the U.S. commercial guide. A raise well above $3.424 billion would support the target. A flat guide would put it at risk.

Palantir Price Prediction 2026–2030

Year
 24/7 Wall St. Price Target

2026
$200.93

2027
$211.98

2028
$222.11

2029
$236.32

2030
$251.45

These figures follow the model’s base-case annualized return of 6.4%. A sustained slowdown in commercial growth or compression of the multiple could pull the path sharply lower.

Contact [email protected] for any questions or corrections.

Sea Limited (SE -1.08%) stock is plunging as the company contemplates some major changes. The company has built cloud infrastructure to better run its gaming, e-commerce, and fintech businesses, and now wants to open its cloud to external customers. Additionally, CEO Forrest Li is considering spinning off the fintech arm, Monee.

The stock has plunged on this news, losing more than 17% of its value since Oct. 15. Although the possibility of that move introduces uncertainty, I think investors should consider the drop in the retail stock a buying opportunity. Here's why.

Image source: The Motley Fool.

The uncertainty surrounding Sea Limited To be sure, Sea Limited's handling of the news surrounding its cloud and fintech moves may have fostered more uncertainty than optimism. Indeed, the demand for cloud infrastructure is massive in today's tech market, especially for AI workloads. That implies the new segment, called Sea Cloud, could perform well. Also, with competitors like Amazon and Alibaba operating cloud businesses, the move is hardly unusual.

Still, even Amazon has had to take on considerable debt to fund its build-out. That causes investors to wonder how much added cost Sea Limited is assuming. The uncertainty may increase with a potential spinoff of Monee. Monee is the company's fastest-growing segment, and Li believes this move could give it added flexibility and a stronger ability to raise capital.

However, Sea Limited benefits from synergies between Monee and the company's other segments. Li did not clarify if or how Monee would still work with Sea if it were a separate company.

Moreover, while such spin-offs usually grant shareholders shares in the new company, investors do not yet know what that allocation would look like. That fact may discourage investors from buying without the specifics of such a deal.

Why investors may want to buy anyway Whatever happens with these moves, it looks increasingly like the selling in Sea Limited stock is overdone. In the first half of 2026, it generated $14.9 billion in revenue, a 47% gain over the same period last year. Of the three segments, Monee's growth was the fastest, increasing by 58% over the same period. Still, even without Monee, this would be a fast-growing company, especially once Sea Cloud launches.

Also, its $869 million in net income for the first half of 2026 is only 7% higher than year-ago levels. Still, it invested more heavily in its operations, a move that should boost its revenue and profits in the long term. Thus, investors should probably give the company some leeway here.

$74.87-$0.82 (-1.08%)

NYSE · As of 11:33 AM ET 10/23/26

Additionally, amid the falling stock price, the company's shares sell at a price-to-earnings (P/E) ratio of 30. Considering how fast the company has grown (even without Monee), Sea Limited's stock looks like an attractive value for the money.

Consider Sea Limited stock Ultimately, the company's growth relative to valuation is alone an excellent reason to buy Sea Limited stock. Indeed, the potentially high cost of a cloud build-out may discourage investors from buying. One can say the same about the uncertainty about a potential Monee spinoff.

However, the company's revenue growth is rapid with or without Monee. When also considering its relatively low P/E ratio, investors are unlikely to go wrong if they plan to buy on the dip.

Every major AI chip bears the fingerprints of one manufacturer, and that company just raised its full-year growth outlook for the third time. Whether the stock's recent pullback is an opportunity or a warning sign depends on a few critical…

The 24/7 Wall St. price target for Taiwan Semiconductor Manufacturing (NYSE:TSM | TSM Price Prediction) is $530.67 over the next 12 months. Our model rates the stock a buy.

24/7 Wall St. Price Target Summary Metric Value Current Price $427.60 Price Target from 24/7 Wall St. $530.67 Upside 24.1% Recommendation BUY Confidence Level 90% A 90% confidence reading is the top of our model’s “high” range.

TSMC makes the leading-edge silicon behind nearly every major AI accelerator, and management has now raised its full-year 2026 growth outlook three times, from close to 30% to approximately 44% in U.S. dollar terms. In management’s own words: “All the AI players are working with TSMC.”

Record Quarter Meets a Post-Earnings Pullback Shares are up 41.79% year to date and 6.57% over the past quarter. They have slipped 3.77% over the past week and 1.63% over the past month. That leaves TSMC 12.3% below its 52-week high of $487.47 and 61.8% above its low of $264.34.

The October 15 earnings report gave the pullback little fundamental support. EPS per ADR came in at $4.60 against a $4.4614 estimate.

Revenue reached $46.72 billion, up 41.2% year over year in dollars and above the high end of guidance. Fourth-quarter guidance of $52.3 billion to $54.3 billion means 58% year-over-year growth at the center.

Why Bulls See $550 and Beyond The 2nm ramp is the engine. It went from 3% of wafer revenue to 8% in a single quarter. Management expects N2 capacity to more than double in 2027, and A14 volume production is set for 2028.

Management had presented AI accelerator growth as a mid to high 50s CAGR through 2029. Asked about that figure, they said: “It probably will be higher.” Of the analysts following TSMC, 6 rate it strong buy, 14 rate it buy and just 1 rates it hold. Our bull scenario reaches $551.68.

Margin Dilution and Capex Are the Risks to Track Gross margin fell 1.3 percentage points from the prior quarter to 66.4%. Management expects dilution from overseas fabs to increase to 3-4% over the next few years.

The 2026 capital budget stands at $60 billion to $64 billion, and non-operating income dropped from NT$95.83 billion to NT$34.59 billion. Cross-strait tensions are still a persistent source of risk for the chip supply chain (European Court of Auditors). Our bear scenario comes to at $442.84.

Dilution is normal on a new node, and margins still sit far above the long-term target of 56% and higher. Demand is higher than supply, management notes, which supports pricing power.

TSMC Trades at a Discount to NVIDIA on Forward Earnings TSMC’s top AI customer is NVIDIA (NASDAQ:NVDA). Its revenue grew 105.85% last quarter, and that growth turns directly into TSMC wafer orders.

Broadcom (NASDAQ:AVGO) relies on outsourced manufacturing for its custom AI accelerators. Its AI semiconductor revenue rose 221% in its latest quarter.

Company Forward P/E Trailing P/E TSMC 21x 27x NVIDIA 25x 27x Broadcom 19x 43x TSMC gets paid no matter which chip design wins the AI race, yet it trades below NVIDIA on forward earnings. Its forward multiple is close to Broadcom’s. Against this group, the 24/7 Wall St. price target looks reasonable, maybe even conservative.

AI Demand Keeps TSMC a BUY The 24/7 Wall St. price target of $530.67 comes with a buy rating and 90% confidence. What tips the scale is a demand gap that management calls “still quite big.”

I’d stay positive as long as the 2nm ramp holds and fourth-quarter revenue comes to within guidance. I’d turn cautious if hyperscaler capex slows or overseas dilution runs past the 3-4% range. For now, the growth outweighs those risks.

Here is where our model projects TSMC could trade if current growth trends and market conditions hold.

Year Price Target from 24/7 Wall St. 2026 $430.37 2027 $530.67 2028 $624.36 2029 $716.18 2030 $767.23 TSMC’s strategy execution supports these projections. The A14 launch and the U.S. expansion could add upside, while rising geopolitical tension could pull results lower.

Contact [email protected] for any questions or corrections.

Compass Wealth Management LLC reduced its holdings in shares of Danaher Corporation (NYSE:DHR – Free Report) by 9.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,242 shares of the conglomerate’s stock after selling 4,464 shares during the period. Danaher comprises approximately 1.9% of Compass Wealth Management LLC’s portfolio, making the stock its 11th biggest holding. Compass Wealth Management LLC’s holdings in Danaher were worth $9,802,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Prime Capital Investment Advisors LLC boosted its stake in shares of Danaher by 0.5% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 9,203 shares of the conglomerate’s stock valued at $2,039,000 after purchasing an additional 45 shares in the last quarter. Veery Capital LLC grew its holdings in shares of Danaher by 3.1% during the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock valued at $350,000 after purchasing an additional 48 shares during the last quarter. Studio Investment Management LLC raised its position in Danaher by 3.3% in the 2nd quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock worth $302,000 after purchasing an additional 51 shares during the period. OLD Second National Bank of Aurora raised its position in Danaher by 0.5% in the 1st quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock worth $2,297,000 after purchasing an additional 57 shares during the period. Finally, Adelphi Trust Co raised its position in Danaher by 2.5% in the 3rd quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock worth $524,000 after purchasing an additional 57 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher News Roundup Here are the key news stories impacting Danaher this week:

Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, ahead of the $1.92 analyst consensus, while revenue increased 8.3% year over year to $6.55 billion. Biotechnology profitability and improving demand across several end markets supported the earnings beat. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves Positive Sentiment: Management raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, and biotechnology orders grew at a mid-teens rate. The company also highlighted margin expansion, improving customer demand, and artificial-intelligence capabilities that could support longer-term drug-discovery growth. Danaher: 3 Key Takeaways for Long-Term Investors Positive Sentiment: Several analysts raised their price targets, including TD Cowen and JPMorgan to $270, Goldman Sachs to $275, and Stifel to $260. The upgrades reflect confidence in the earnings beat, improved execution, and the stronger profit outlook. Neutral Sentiment: New CEO Julie Montgomery emphasized the need to improve execution and innovation. Investors are watching whether management can convert the company’s AI and biotechnology investments into sustained growth. Danaher Posts First Earnings Under New CEO Negative Sentiment: Revenue was approximately in line with, or slightly below, estimates, while analysts cited tariff pressure and a cautious 2027 outlook. At roughly 41 times earnings, Danaher’s valuation leaves limited room for operational disappointment, contributing to the negative investor reaction despite the quarterly beat. Wall Street Analysts Forecast Growth Several analysts have weighed in on the stock. JPMorgan Chase & Co. boosted their price target on shares of Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $240.00 target price on shares of Danaher in a research note on Wednesday, July 22nd. The Goldman Sachs Group restated a “buy” rating and set a $275.00 target price on shares of Danaher in a report on Thursday. Robert W. Baird raised their price target on Danaher from $246.00 to $254.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Morgan Stanley lifted their price target on Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $242.91. View Our Latest Stock Report on Danaher

Danaher Trading Down 1.7% Shares of DHR opened at $229.86 on Friday. The stock has a market capitalization of $161.59 billion, a P/E ratio of 40.83, a PEG ratio of 2.95 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The firm has a fifty day simple moving average of $215.76 and a two-hundred day simple moving average of $197.12. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80.

Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.92 by $0.19. Danaher had a net margin of 16.91% and a return on equity of 11.22%. The business had revenue of $6.55 billion for the quarter, compared to analyst estimates of $6.56 billion. During the same quarter last year, the firm earned $1.89 EPS. The company’s revenue was up 8.3% on a year-over-year basis. On average, research analysts anticipate that Danaher Corporation will post 8.51 EPS for the current year.

Danaher Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Danaher Company Profile (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

Featured Articles Five stocks we like better than Danaher Is Texas Instruments Setting Up for Its Next Big Breakout? Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was Tesla’s Flying-Car Hype Hits an Earnings Reality Check Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

In its upcoming report, ServiceNow (NOW - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.02 per share, reflecting an increase of 6.3% compared to the same period last year. Revenues are forecasted to be $4.09 billion, representing a year-over-year increase of 20%.

The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.

Bearing this in mind, let's now explore the average estimates of specific ServiceNow metrics that are commonly monitored and projected by Wall Street analysts.

The combined assessment of analysts suggests that 'Revenues- Professional services and other' will likely reach $113.57 million. The estimate points to a change of +5.2% from the year-ago quarter.

According to the collective judgment of analysts, 'Revenues- Subscription' should come in at $3.98 billion. The estimate indicates a year-over-year change of +20.6%.

Analysts expect 'Current Remaining Performance Obligations(cRPO) - GAAP' to come in at $13.56 billion. Compared to the current estimate, the company reported $11.35 billion in the same quarter of the previous year.

Analysts predict that the 'Remaining Performance Obligations (RPO) - GAAP' will reach $29.32 billion. The estimate is in contrast to the year-ago figure of $24.30 billion.

The consensus estimate for 'Gross Profit (Non-GAAP)- Subscription' stands at $3.21 billion. The estimate compares to the year-ago value of $2.74 billion.

It is projected by analysts that the 'Gross Profit (Non-GAAP)- Professional services and other' will reach $6.03 million. The estimate compares to the year-ago value of $12.00 million.

View all Key Company Metrics for ServiceNow here>>>

Shares of ServiceNow have experienced a change of +14% in the past month compared to the -1.2% move of the Zacks S&P 500 composite. With a Zacks Rank #5 (Strong Sell), NOW is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Key Takeaways NXPI expects Q3 revenues of $3.77 billion, up 18.8% year over year, with EPS consensus at $4.14.Automotive revenues are expected to rise 11.9%, while Industrial & IoT is projected to grow 38.5%.Communications Infrastructure revenue is seen up 50.2%, but mobile revenue may fall 5.8% amid constraints. NXP Semiconductors (NXPI - Free Report) is scheduled to report third-quarter 2026 results on Oct. 27, after market close.

NXPI expects third-quarter revenues between $3.65 billion and $3.85 billion. The Zacks Consensus Estimate for revenues is pegged at $3.77 billion, indicating an increase of 18.8% year over year.

For the third quarter, NXP Semiconductors anticipates non-GAAP earnings per share between $3.89 and $4.32. The consensus mark for earnings is pinned at $4.14 per share, revised up by a penny over the past seven days, suggesting an increase of 33.1% year over year.

In the trailing four quarters, NXPI’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 1.5%.

Let’s see how things are shaping up for the upcoming quarterly results.

Factors to Consider for NXPINXP Semiconductors' third-quarter performance is expected to have benefited from continued strength in its Automotive business. Growth is likely to have been driven by the growing adoption of software-defined vehicles, vehicle electrification and connectivity solutions. Design wins for the S32N and S32K processor platforms and next-generation automotive Ethernet switches are also expected to have supported growth in the to-be-reported quarter.

The company expects revenues from the Automotive end market to be up in the low-double digits on a year-over-year basis. The Zacks Consensus Estimate for Automotive revenues is currently pegged at $2.05 billion, indicating an increase of 11.9% from the year-ago quarter.

Recovery in the Industrial & Internet of Things (IoT) market is expected to have remained a key growth driver during the third quarter. Demand is likely to have been supported by industrial processing solutions, including the i.MX, RT and MCX product families, along with strength in factory automation, energy storage and data center applications. The company expects revenues from Industrial & IoT end markets to be up in the high-30% range year over year. The Zacks Consensus Estimate for NXPI’s Industrial & IoT revenues is pegged at $801.5 million, indicating a year-over-year increase of 38.5%.

The Communications Infrastructure & Other segment’s third-quarter prospects are expected to have benefited from growing exposure to data center infrastructure, digital networking products and continued strength in RFID solutions. NXPI expects revenues from Communications Infrastructure & Other end markets to increase about 50% on a year-over-year basis. The Zacks Consensus Estimate for the Communications Infrastructure & Others segment revenues is pegged at $490.6 million, indicating an increase of 50.2% on a year-over-year basis.

However, NXPI expects revenues from the Mobile end market to decline in the mid-single-digit percentage range on a year-over-year basis in the third quarter. Management noted that memory shortages and other component constraints are affecting some customers’ ability to meet demand. This could limit demand for secure mobile transaction products. The Zacks Consensus Estimate of $405.3 million for the Mobile end market implies a year-over-year decline of 5.8% from the year-ago quarter.

Further, NXPI's third-quarter performance is expected to have been hurt by higher input costs and supply chain bottlenecks as the company faces inflation in components such as substrates, precious metals and other back-end materials. Management noted that certain parts of the supply chain remain tight, leading to inflationary cost pressures. While the company is using operational efficiency measures to offset these costs through selective price adjustments, higher costs could put pressure on margins if they are not fully offset.

What Our Proven Model Says for NXPI’s Q2 EarningsOur proven model does not conclusively predict an earnings beat for NXP Semiconductors this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here.

NXP Semiconductors has an Earnings ESP of -0.27% and carries a Zacks Rank #2 at present. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Stocks to ConsiderHere are some stocks worth considering, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.

Seagate Technology (STX - Free Report) has an Earnings ESP of +2.49% and sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Seagate Technology is set to report first-quarter fiscal 2027 results on Oct. 27. The Zacks Consensus Estimate for Seagate Technology’s first-quarter fiscal 2027 earnings is pegged at $7.40 per share, up by 6 cents over the past seven days, indicating a rise of 183.5% from the year-ago quarter’s reported figure.

Amphenol (APH - Free Report) has an Earnings ESP of +1.12% and carries a Zacks Rank #2 at present.

Amphenol is set to report third-quarter 2026 results on Oct. 28. The Zacks Consensus Estimate for Amphenol’s third-quarter 2026 earnings is pegged at 73 cents per share, up by a penny over the past seven days, indicating a rise of 55.3% from the year-ago quarter’s reported figure.

Corning (GLW - Free Report) has an Earnings ESP of +0.68% and a Zacks Rank #2 at present.

Corning is slated to report third-quarter 2026 results on Oct. 27. The Zacks Consensus Estimate for Corning’s third-quarter 2026 earnings is pegged at 88 cents per share, unchanged over the past 30 days, indicating a rise of 31.3% from the year-ago quarter’s reported figure.

Key Takeaways ADP's Q1 revenues are projected to rise 5.6% y/y to $5.5B, while EPS is expected to grow 11.7% to $2.78.ES revenues are expected to grow 5.3%, fueled by HR outsourcing demand and business bookings.ADP's PEO revenues are projected to rise 5.8%, while interest on client funds is expected to grow 15.9%.
ADP (ADP - Free Report) is scheduled to release first-quarter fiscal 2027 results on Oct. 28, before market open.

ADP has a decent earnings surprise history, surpassing the Zacks Consensus Estimate in the trailing four quarters, with an average surprise of 2.1%.

ADP’s Q1 ExpectationsThe Zacks Consensus Estimate for the top line is set at $5.5 billion, indicating 5.6% year-over-year growth. The consensus estimate for the Employer Services (ES) segment revenues is pinned at $3.7 billion, indicating 5.3% year-over-year growth.

The ES segment is expected to have benefited from solid business bookings, persistent demand for HR outsourcing solutions, and expansion across domestic and international markets.

The segment is expected to have experienced significant growth from the growing adoption of ADP Lyric HCM, Global Payroll and WorkForce Suite. Additional support is expected from investments in AI-driven sales tools, prudent pricing contribution and healthy client retention.

The Zacks Consensus Estimate for Professional Employer Organization services revenues is pegged at $1.8 billion, indicating a 5.8% year-over-year gain. Continued business bookings growth and an expanding worksite employee base are anticipated to have supported this segment’s growth. Growth across the PEO segment is likely to have been further supported by enhanced customer satisfaction and stable retention.

The consensus mark for Interest on Funds held for clients is at $332.3 million, suggesting 15.9% year-over-year growth. Higher average investment yields and expanding client fund balances are expected to have boosted this segment’s revenue growth.

The consensus estimate for earnings per share is set at $2.78, implying year-over-year growth of 11.7%. The bottom line is anticipated to have improved on the back of AI-driven operational efficiencies and service delivery cost strip-down.

What Our Model Says About ADPOur proven model does not conclusively predict an earnings beat for ADPthis time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.

ADP has an Earnings ESP of 0.00% and a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Stocks to ConsiderHere are a few stocks from the broader Computer and Technology sector, which, according to our model, have the right combination of elements to beat on earnings this season.

Affirm (AFRM - Free Report) : The Zacks Consensus Estimate for the company’s first-quarter fiscal 2027 revenues is pinned at $1.2 billion, indicating a 30% year-over-year jump. For earnings, the consensus mark is set at 35 cents per share, suggesting 52.2% year-over-year growth. The company beat the Zacks Consensus Estimate in the past four quarters, the average surprise being 379.4%.

AFRM has an Earnings ESP of +11.03% and a Zacks Rank #2 at present.

The company is scheduled to declare first-quarter fiscal 2027 results on Nov. 5.

Amphenol (APH - Free Report) : The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues is kept at $9.4 billion, implying 52.4% year-over-year growth. For earnings, the consensus mark is pinned at 73 cents per share, suggesting a 55.3% jump from that reported in the year-ago quarter. The company beat the Zacks Consensus Estimate in the past four quarters, with an average surprise of 11.8%.

APH currently has an Earnings ESP of +1.72% and a Zacks Rank #2. The company is scheduled to declare third-quarter 2026 results on Oct. 28.

SummaryAGNC Investment Corp. offers a high 16% dividend yield but suffers from persistent book value per share decay.Despite strong income production and internal management, AGNC's history of dilution and poor performance during volatility limits its total return potential.AGNC currently trades at a 1.23x price-to-book, the high end of its historical range, raising the risk of multiple compression.I rate AGNC a Hold, expecting 6–8% annual total returns, as dividend yield is offset by ongoing book value erosion.Looking for option income ideas that focus on capital preservation? I offer this and much more at my exclusive investing ideas service, Option Income Builder. Learn More » deepblue4you/iStock via Getty Images

When it comes to building an income-producing portfolio, inevitably investors stumble across mortgage REITs: companies that buy up residential and commercial mortgages and earn interest on the spread between their borrowing costs and whatever interest rates the

11.53K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Canadian National (CNI - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 30. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis railroad is expected to post quarterly earnings of $1.49 per share in its upcoming report, which represents a year-over-year change of +12%.

Revenues are expected to be $3.27 billion, up 8.1% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 1.01% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for CN?For CN, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.57%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that CN will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that CN would post earnings of $1.39 per share when it actually produced earnings of $1.50, delivering a surprise of +7.91%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

CN doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Expected Results of an Industry PlayerCanadian Pacific Kansas City (CP - Free Report) , another stock in the Zacks Transportation - Rail industry, is expected to report earnings per share of $0.95 for the quarter ended September 2026. This estimate points to a year-over-year change of +18.8%. Revenues for the quarter are expected to be $3.02 billion, up 13.6% from the year-ago quarter.

The consensus EPS estimate for Canadian Pacific Kansas City has been revised 0.4% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -1.03%.

When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that Canadian Pacific Kansas City will beat the consensus EPS estimate. Over the last four quarters, the company surpassed EPS estimates just once.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

The upcoming report from Fortinet (FTNT - Free Report) is expected to reveal quarterly earnings of $0.86 per share, indicating an increase of 16.2% compared to the year-ago period. Analysts forecast revenues of $2.06 billion, representing an increase of 19.5% year over year.

Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

In light of this perspective, let's dive into the average estimates of certain Fortinet metrics that are commonly tracked and forecasted by Wall Street analysts.

The consensus estimate for 'Revenue- Services' stands at $1.33 billion. The estimate suggests a change of +14.1% year over year.

Analysts expect 'Revenue- Product' to come in at $720.87 million. The estimate suggests a change of +28.9% year over year.

Analysts' assessment points toward 'Revenue- Services- Security subscription' reaching $770.45 million. The estimate points to a change of +14.7% from the year-ago quarter.

According to the collective judgment of analysts, 'Revenue- Services- Technical support and other' should come in at $572.35 million. The estimate indicates a year-over-year change of +16%.

Analysts predict that the 'Total billings (Non-GAAP)' will reach $2.30 billion. Compared to the current estimate, the company reported $1.81 billion in the same quarter of the previous year.

The combined assessment of analysts suggests that 'Total deferred revenue' will likely reach $7.92 billion. Compared to the present estimate, the company reported $6.65 billion in the same quarter last year.

Based on the collective assessment of analysts, 'Gross profit- Product Non-GAAP' should arrive at $494.12 million. Compared to the present estimate, the company reported $380.60 million in the same quarter last year.

Analysts forecast 'Gross profit- Service Non-GAAP' to reach $1.16 billion. Compared to the present estimate, the company reported $1.03 billion in the same quarter last year.

The average prediction of analysts places 'Gross profit- Product' at $485.44 million. The estimate compares to the year-ago value of $378.60 million.

It is projected by analysts that the 'Gross profit- Services' will reach $1.15 billion. Compared to the present estimate, the company reported $1.01 billion in the same quarter last year.

View all Key Company Metrics for Fortinet here>>>

Shares of Fortinet have experienced a change of -3.2% in the past month compared to the -1.2% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), FTNT is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Rithm (RITM - Free Report) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.54 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +7.84%. A quarter ago, it was expected that this real estate investment trust would post earnings of $0.5 per share when it actually produced earnings of $0.6, delivering a surprise of +20%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Rithm, which belongs to the Zacks Financial - Miscellaneous Services industry, posted revenues of $1.76 billion for the quarter ended September 2026, surpassing the Zacks Consensus Estimate by 17.71%. This compares to year-ago revenues of $1.11 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Rithm shares have lost about 20.4% since the beginning of the year versus the S&P 500's gain of 12%.

What's Next for Rithm?While Rithm has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Rithm was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.64 on $1.7 billion in revenues for the coming quarter and $2.25 on $5.85 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Financial - Miscellaneous Services is currently in the bottom 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Axos Financial (AX - Free Report) , is yet to report results for the quarter ended September 2026. The results are expected to be released on October 29.

This bank holding company is expected to post quarterly earnings of $2.25 per share in its upcoming report, which represents a year-over-year change of +8.7%. The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level.

Axos Financial's revenues are expected to be $386.08 million, up 19.4% from the year-ago quarter.

Axxcess Wealth Management LLC reduced its stake in CSX Corporation (NASDAQ:CSX – Free Report) by 12.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,721 shares of the transportation company’s stock after selling 12,913 shares during the period. Axxcess Wealth Management LLC’s holdings in CSX were worth $4,266,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in CSX during the 2nd quarter worth $7,655,277,000. XXEC Inc. bought a new stake in CSX during the 2nd quarter valued at $765,595,000. Bank of America Corp DE bought a new stake in CSX during the 2nd quarter valued at $1,598,962,000. Bank of New York Mellon Corp purchased a new stake in shares of CSX in the 2nd quarter worth $950,325,000. Finally, Legal & General Group Plc purchased a new stake in shares of CSX in the 2nd quarter worth $747,001,000. 73.57% of the stock is currently owned by institutional investors.

CSX Trading Up 6.8% NASDAQ CSX opened at $51.67 on Friday. CSX Corporation has a 52 week low of $33.63 and a 52 week high of $53.60. The company has a 50 day moving average price of $48.69 and a 200 day moving average price of $47.59. The company has a quick ratio of 0.72, a current ratio of 0.82 and a debt-to-equity ratio of 1.22. The firm has a market cap of $95.72 billion, a PE ratio of 29.87, a price-to-earnings-growth ratio of 2.28 and a beta of 1.21.

CSX (NASDAQ:CSX – Get Free Report) last released its quarterly earnings results on Wednesday, October 21st. The transportation company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.53 by $0.04. CSX had a net margin of 23.97% and a return on equity of 26.31%. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period in the previous year, the company earned $0.44 earnings per share. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. As a group, sell-side analysts forecast that CSX Corporation will post 1.99 EPS for the current fiscal year. CSX Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 15th. Investors of record on Monday, November 30th will be paid a $0.14 dividend. The ex-dividend date is Monday, November 30th. This represents a $0.56 dividend on an annualized basis and a yield of 1.1%. CSX’s dividend payout ratio (DPR) is 32.37%.

Wall Street Analysts Forecast Growth CSX has been the subject of a number of research reports. UBS Group set a $54.00 price objective on shares of CSX in a research note on Thursday. Bank of America increased their target price on shares of CSX from $55.00 to $57.00 and gave the stock a “buy” rating in a report on Thursday. Stifel Nicolaus set a $54.00 target price on shares of CSX in a research report on Thursday, July 23rd. BMO Capital Markets restated a “market perform” rating and issued a $52.00 price target (up from $49.00) on shares of CSX in a report on Thursday, July 23rd. Finally, Citigroup restated a “cautious” rating on shares of CSX in a report on Wednesday, October 7th. Eighteen research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.83.

Get Our Latest Analysis on CSX

Key Headlines Impacting CSX Here are the key news stories impacting CSX this week:

Positive Sentiment: Q3 earnings and revenue beat expectations. CSX reported $0.57 in adjusted EPS versus the $0.53 consensus estimate and $4.02 billion in revenue versus expectations of $3.96 billion. Revenue increased 12% year over year, while net earnings reached $1.05 billion. CSX increases earnings and revenue Positive Sentiment: Volumes and margins improved materially. Total volume rose 5%, with intermodal volume up 7% to a record level. Operating income increased 44% to $1.57 billion, and the operating margin expanded to 39.1%. Management also cited a 3% reduction in nonfuel costs, supporting the view that the improvement was not solely driven by fuel surcharges. CSX: 3 Key Takeaways for Long-Term Investors Positive Sentiment: Management offered constructive growth targets. CSX projects high-single-digit revenue growth in 2026 and is targeting more than 350 basis points of operating-margin expansion. Higher rail volumes may also benefit CSX relative to trucking companies as elevated fuel costs pressure truck transportation. CSX projects 2026 revenue growth Positive Sentiment: Analysts raised their estimates. Bank of America increased its price target to $57 from $55 with a Buy rating, while JPMorgan raised its target to $58 and maintained an Overweight rating. CSX Analysts Boost Their Forecasts Neutral Sentiment: CSX announced the elimination of more than 100 management positions, which could improve efficiency but may also signal ongoing cost-control efforts. CSX eliminates management positions Negative Sentiment: Risks include valuation concerns and conflicting analyst views: Morgan Stanley maintained a $32 Sell target, while Raymond James reduced its target to $53. A law firm is also investigating potential class-action claims related to a reported customer-data breach. CSX Sell Rating Maintained About CSX (Free Report)

CSX Corporation is a transportation company whose primary business is freight railroading through its CSX Transportation subsidiary. The company operates an extensive rail network across the eastern United States, serving major industrial centers, population hubs, ports and distribution markets.

CSX transports a broad range of products, including chemicals, agricultural and food products, forest products, minerals, metals, automotive goods and other manufactured merchandise. Its services also include intermodal transportation, which combines rail service with trucks and containers, as well as the movement of coal and other bulk commodities.

The company traces its roots to the formation of CSX Corporation in 1980 through the merger of Chessie System and Seaboard Coast Line Industries.

Featured Stories Five stocks we like better than CSX Is Texas Instruments Setting Up for Its Next Big Breakout? Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was Tesla’s Flying-Car Hype Hits an Earnings Reality Check Want to see what other hedge funds are holding CSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CSX Corporation (NASDAQ:CSX – Free Report).

Receive News & Ratings for CSX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSX and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways DuPont launches AmberChrom SIL silica gel to enhance peptide purification, including GLP-1 therapeutics.Available in C8 and C18 chemistries, the new media offers high resolution, stability and scalability.DuPont's new media integrates with existing chromatography resins to optimize purity, yield and recovery.
DuPont de Nemours, Inc. (DD - Free Report) has launched AmberChrom SIL silica gel, a new reverse-phase silica-based chromatography media designed to support the purification and manufacturing of peptide therapeutics, including glucagon-like peptide-1 (GLP-1) receptor agonists. The launch expands DuPont’s bioprocessing purification portfolio and strengthens its suitability for high-purity polishing.

Growing demand for peptide therapeutics for the treatment of diabetes, obesity and other chronic conditions is increasing the need for efficient purification technologies at a larger scale. AmberChrom SIL silica gel is designed to help biopharmaceutical manufacturers meet stringent purity requirements while maintaining high yields.

Available in C8 and C18 chemistries, the new product offers high resolution, stability and scalability for demanding peptide separations. It can be used during multiple stages of purification to address diverse impurity profiles and specific process requirements.

DuPont’s latest launch can also be integrated with its existing chromatography technologies, including AmberChrom XT, AmberChrom TQ1 and CG resins. Combining silica-based and polymeric chromatography technologies with a single purification workflow enables manufacturers to optimize purity, yield and recovery across multiple stages.

The launch reinforces DuPont’s focus on expanding its solutions to address evolving needs by offering process development and manufacturing scale-up to optimize purification workflows and achieve purity targets.

Shares of DD have lost 44.4% over the past year against the 1.2% rise of its industry. 

Image Source: Zacks Investment Research

DD’s Zacks Rank & Key PicksDDcurrently carries a Zacks Rank #3 (Hold).

Better-ranked stocks in the Basic Materials space are Reliance, Inc. (RS - Free Report) , Cabot Corporation (CBT - Free Report) and Avient Corporation (AVNT - Free Report) .

RS currently sports a Zacks Rank #1 (Strong Buy), while CBT and AVNT carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here

The Zacks Consensus Estimate for RS’ 2026 earnings is pegged at $23.70 per share, indicating a 66.2% year-over-year surge. RSshares have gained 50.8% over the past year.

The Zacks Consensus Estimate for CBT’s current fiscal-year earnings is pinned at $6.35 per share. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, with an average surprise of 4.56%. CBTshares have gained 4.2% over the past year.

The Zacks Consensus Estimate for AVNT’s 2026 earnings is pegged at $3.2 per share, indicating a year-over-year rise of 13.48%. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%.

Key Takeaways Enphase Energy's Q3 sales and earnings are expected to decline 26% and 47.8%, respectively, year over year.ENPH's IQ9 microinverter launches, improving U.S. demand and European momentum may support Q3 performance.ENPH faces tariff-driven margin pressure and demand risks from high rates and cautious distributors. Enphase Energy, Inc. (ENPH - Free Report) is scheduled to report third-quarter 2026 results on Oct. 27, 2026, after market close.

Enphase Energy reported earnings in line with estimates in the last reported quarter.

Factors to Note Ahead of ENPH’s Q3 ResultsDuring the third quarter, Enphase Energy is expected to have benefited from improving demand in the United States and continued momentum in Europe. Higher global sell-through and battery shipments are likely to have supported its performance.

In June 2026, Enphase Energy launched its IQ9 residential microinverters across the United States and key European markets, followed by Australia and New Zealand in July. The company also began shipping the IQ9S-3P commercial microinverter. These launches are expected to strengthen its solar portfolio and drive customer adoption and product shipments.

Growing demand for battery storage and expansion in the commercial solar market is likely to have supported ENPH's overall performance in the to-be-reported quarter.

ENPH's investments in product innovation, battery technology and financing initiatives, along with efforts to improve affordability, are anticipated to have supported its performance.

Meanwhile, reciprocal tariffs remain a key headwind, weighing on gross margins and profitability. Cautious distributors, elevated interest rates and macroeconomic uncertainty could also constrain demand.

Q3 Expectations for ENPHThe Zacks Consensus Estimate for ENPH’s sales stands at $303.7 million, which suggests a decline of 26% from the year-ago reported number. 

The consensus estimate for earnings per share is pinned at 47 cents, which indicates a year-over-year fall of 47.8%.

The Zacks Consensus Estimate for total megawatts (MWs) shipped is pegged at 694.12 MW, down 11.5% from the figure registered in the year-ago quarter.

What the Zacks Model UnveilsOur proven model does not conclusively predict an earnings beat for Enphase Energy this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is not the case here.

Earnings ESP: Enphase Energy’s Earnings ESP is +6.38%. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.

Zacks Rank: Enphase Energy currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank stocks here.

Stocks to ConsiderHere are three companies from the same sector that have the right combination of elements to post an earnings beat this reporting cycle.

SolarEdge Technologies (SEDG - Free Report) is set to report third-quarter 2026 earnings on Nov. 4, 2026. It has an Earnings ESP of +198.04% and a Zacks Rank of 3.

The Zacks Consensus Estimate for SEDG’s earnings is pegged at two cents per share. The consensus estimate for its sales is pegged at $329.1 million, indicating a year-over-year decline of 3.3%.

ONEOK (OKE - Free Report) is set to report third-quarter 2026 earnings on Oct. 27, 2026. It has an Earnings ESP of +1.74% and a Zacks Rank of 3.

The Zacks Consensus Estimate for OKE’s earnings is pegged at $1.46 per share. The consensus estimate for its sales is pegged at $11.77 billion, indicating year-over-year growth of 36.3%.

Array Technologies (ARRY - Free Report) is set to report third-quarter 2026 earnings on Nov. 5, 2026. It has an Earnings ESP of +15.06% and a Zacks Rank of 3.

The Zacks Consensus Estimate for ARRY’s earnings is pegged at 10 cents per share. The consensus estimate for its sales is pegged at $322.2 million, indicating a year-over-year decline of 18.1%.

OneMain Holdings (OMF - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 30. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis consumer finance company is expected to post quarterly earnings of $1.59 per share in its upcoming report, which represents a year-over-year change of -16.3%.

Revenues are expected to be $1.13 billion, up 5.3% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 5.42% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for OneMain?For OneMain, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that OneMain will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that OneMain would post earnings of $1.31 per share when it actually produced earnings of $1.31, delivering no surprise.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

OneMain doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

The upcoming report from American Electric Power (AEP - Free Report) is expected to reveal quarterly earnings of $2.04 per share, indicating an increase of 13.3% compared to the year-ago period. Analysts forecast revenues of $6.58 billion, representing an increase of 9.5% year over year.

Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 3.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

Given this perspective, it's time to examine the average forecasts of specific AEP metrics that are routinely monitored and predicted by Wall Street analysts.

The average prediction of analysts places 'Total Revenues- Generation & Marketing' at $567.21 million. The estimate points to a change of -18.3% from the year-ago quarter.

Analysts expect 'Total Revenues- Transmission and Distribution Utilities' to come in at $1.89 billion. The estimate indicates a year-over-year change of +12.4%.

According to the collective judgment of analysts, 'Total Revenues- Vertically Integrated Utilities' should come in at $4.19 billion. The estimate points to a change of +19.4% from the year-ago quarter.

Analysts predict that the 'Total Revenues- AEP Transmission Holdco' will reach $631.34 million. The estimate points to a change of +10.1% from the year-ago quarter.

Based on the collective assessment of analysts, 'Operating Earnings (non-GAAP)- Vertically Integrated Utilities' should arrive at $716.50 million. The estimate compares to the year-ago value of $573.50 million.

Analysts forecast 'Operating Earnings (non-GAAP)- Transmission & Distribution Utilities' to reach $291.51 million. Compared to the current estimate, the company reported $259.10 million in the same quarter of the previous year.

It is projected by analysts that the 'Operating Earnings (non-GAAP)- Generation & Marketing' will reach $29.67 million. Compared to the present estimate, the company reported $48.40 million in the same quarter last year.

Analysts' assessment points toward 'Operating Earnings (non-GAAP)- AEP Transmission Holdco' reaching $219.92 million. Compared to the present estimate, the company reported $199.90 million in the same quarter last year.

View all Key Company Metrics for AEP here>>>

Over the past month, AEP shares have recorded returns of +11.1% versus the Zacks S&P 500 composite's -1.2% change. Based on its Zacks Rank #2 (Buy), AEP will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

First Hawaiian (FHB - Free Report) came out with quarterly earnings of $0.52 per share, missing the Zacks Consensus Estimate of $0.6 per share. This compares to earnings of $0.59 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -13.33%. A quarter ago, it was expected that this bank holding company would post earnings of $0.6 per share when it actually produced earnings of $0.6, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

First Hawaiian, which belongs to the Zacks Banks - West industry, posted revenues of $230.23 million for the quarter ended September 2026, surpassing the Zacks Consensus Estimate by 0.23%. This compares to year-ago revenues of $226.39 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

First Hawaiian shares have added about 3.3% since the beginning of the year versus the S&P 500's gain of 12%.

What's Next for First Hawaiian?While First Hawaiian has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for First Hawaiian was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.62 on $291.79 million in revenues for the coming quarter and $2.39 on $970.97 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - West is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Sierra Bancorp (BSRR - Free Report) , another stock in the same industry, has yet to report results for the quarter ended September 2026.

This parent company of Bank of the Sierra is expected to post quarterly earnings of $0.90 per share in its upcoming report, which represents a year-over-year change of +25%. The consensus EPS estimate for the quarter has been revised 1.2% lower over the last 30 days to the current level.

Sierra Bancorp's revenues are expected to be $39.25 million, down 2% from the year-ago quarter.

IonQ, Inc. (IONQ - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Over the past month, shares of this company have returned -30.7%, compared to the Zacks S&P 500 composite's -1.2% change. During this period, the Zacks Computer - Integrated Systems industry, which IonQ falls in, has lost 18.5%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

For the current quarter, IonQ is expected to post a loss of $0.30 per share, indicating a change of +91.6% from the year-ago quarter. The Zacks Consensus Estimate has changed -38.6% over the last 30 days.

The consensus earnings estimate of -$1.26 for the current fiscal year indicates a year-over-year change of +30.8%. This estimate has changed -40.3% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $1.17 indicates a change of +7% from what IonQ is expected to report a year ago. Over the past month, the estimate has changed +19.4%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, IonQ is rated Zacks Rank #4 (Sell).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of IonQ, the consensus sales estimate of $145.29 million for the current quarter points to a year-over-year change of +264.4%. The $455.01 million and $810.73 million estimates for the current and next fiscal years indicate changes of +250% and +78.2%, respectively.

Last Reported Results and Surprise HistoryIonQ reported revenues of $80.05 million in the last reported quarter, representing a year-over-year change of +286.9%. EPS of -$0.33 for the same period compares with -$0.7 a year ago.

Compared to the Zacks Consensus Estimate of $66.36 million, the reported revenues represent a surprise of +20.63%. The EPS surprise was -13.79%.

Over the last four quarters, the company surpassed EPS estimates just once. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

IonQ is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about IonQ. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.

Wall Street analysts forecast that KLA (KLAC - Free Report) will report quarterly earnings of $1.18 per share in its upcoming release, pointing to a year-over-year increase of 34.1%. It is anticipated that revenues will amount to $4.05 billion, exhibiting an increase of 26.1% compared to the year-ago quarter.

The consensus EPS estimate for the quarter has undergone an upward revision of 0.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.

Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

In light of this perspective, let's dive into the average estimates of certain KLA metrics that are commonly tracked and forecasted by Wall Street analysts.

The average prediction of analysts places 'Revenues- Specialty Semiconductor Process' at $173.38 million. The estimate indicates a change of +44.8% from the prior-year quarter.

Analysts expect 'Revenues- Service' to come in at $853.57 million. The estimate suggests a change of +14.6% year over year.

It is projected by analysts that the 'Revenues- Product' will reach $3.16 billion. The estimate indicates a change of +28.2% from the prior-year quarter.

Analysts predict that the 'Revenues- Semiconductor Process Control' will reach $3.63 billion. The estimate indicates a year-over-year change of +25.4%.

The combined assessment of analysts suggests that 'Revenues- PCB and Component Inspection' will likely reach $207.11 million. The estimate indicates a year-over-year change of +9.3%.

The consensus estimate for 'Geographic Revenues- China' stands at $1.00 billion. The estimate points to a change of -20.7% from the year-ago quarter.

The consensus among analysts is that 'Geographic Revenues- Rest of Asia' will reach $140.74 million. The estimate indicates a year-over-year change of +33.4%.

Analysts forecast 'Geographic Revenues- North America' to reach $522.77 million. The estimate indicates a year-over-year change of +75.5%.

The collective assessment of analysts points to an estimated 'Geographic Revenues- Europe & Israel' of $180.94 million. The estimate indicates a year-over-year change of +19.8%.

Analysts' assessment points toward 'Geographic Revenues- Taiwan' reaching $1.15 billion. The estimate indicates a change of +44.3% from the prior-year quarter.

According to the collective judgment of analysts, 'Geographic Revenues- Korea' should come in at $683.67 million. The estimate indicates a year-over-year change of +128.4%.

Based on the collective assessment of analysts, 'Geographic Revenues- Japan' should arrive at $341.37 million. The estimate suggests a change of +15.6% year over year.

View all Key Company Metrics for KLA here>>>

Over the past month, shares of KLA have returned -21% versus the Zacks S&P 500 composite's -1.2% change. Currently, KLAC carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Analysts on Wall Street project that O'Reilly Automotive (ORLY - Free Report) will announce quarterly earnings of $0.93 per share in its forthcoming report, representing an increase of 9.4% year over year. Revenues are projected to reach $5 billion, increasing 6.2% from the same quarter last year.

The current level reflects an upward revision of 0.7% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.

Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

Bearing this in mind, let's now explore the average estimates of specific O'Reilly Automotive metrics that are commonly monitored and projected by Wall Street analysts.

Analysts predict that the 'Sales to Do-It-Yourself Customers' will reach $2.41 billion. The estimate indicates a year-over-year change of +4.8%.

Analysts expect 'Other sales and sales adjustments' to come in at $96.83 million. The estimate indicates a change of +4% from the prior-year quarter.

It is projected by analysts that the 'Sales to professional service provider customers' will reach $2.49 billion. The estimate indicates a change of +8.1% from the prior-year quarter.

According to the collective judgment of analysts, 'Comparable store sales - YoY change' should come in at 4.4%. The estimate is in contrast to the year-ago figure of 5.6%.

Analysts' assessment points toward 'Square footage - Total' reaching 53 millions of square feet. The estimate compares to the year-ago value of 51 millions of square feet.

Based on the collective assessment of analysts, 'Number of stores opened' should arrive at 59 . Compared to the present estimate, the company reported 55 in the same quarter last year.

The collective assessment of analysts points to an estimated 'Total Stores at Beginning of the period' of 6,716 . The estimate is in contrast to the year-ago figure of 6,483 .

The consensus estimate for 'Number of stores - Total' stands at 6,754 . The estimate compares to the year-ago value of 6,538 .

The combined assessment of analysts suggests that 'Ending domestic store count' will likely reach 6,592 . The estimate is in contrast to the year-ago figure of 6,406 .

The average prediction of analysts places 'Mexico Stores at End of the Period' at 132 . Compared to the present estimate, the company reported 107 in the same quarter last year.

The consensus among analysts is that 'Sales per weighted-average square foot' will reach $93.68 million. Compared to the current estimate, the company reported $90.80 million in the same quarter of the previous year.

Analysts forecast 'Total employment' to reach 93,732 . Compared to the present estimate, the company reported 93,269 in the same quarter last year.

View all Key Company Metrics for O'Reilly Automotive here>>>

Shares of O'Reilly Automotive have demonstrated returns of +6.7% over the past month compared to the Zacks S&P 500 composite's -1.2% change. With a Zacks Rank #3 (Hold), ORLY is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Key Takeaways Baker Hughes' Q3 revenues are estimated at $7.78 billion, reflecting 11% growth from the prior-year quarter. BKR's Q3 earnings estimate rose over the past month to 64 cents per share but implies a 5.9% y/y decline. Higher oil prices may boost BKR's demand, while Middle East tensions could hurt profits via delays & costs. Baker Hughes (BKR - Free Report) is set to report third-quarter 2026 results on Oct 27, after market close.

In the last reported quarter, its earnings of 64 cents per share beat the Zacks Consensus Estimate of 51 cents, driven by strong Oilfield Services & Equipment execution, firm Industrial & Energy Technology profitability and record order momentum. The oilfield services player’s earnings topped the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 17.4%. This is depicted in the graph below:

Estimate Trend for BKRThe Zacks Consensus Estimate for third-quarter earnings per share of 64 cents has been revised upward over the past 30 days. The estimated figure indicates a 5.9% decline from the prior-year reported number.

The Zacks Consensus Estimate for revenues of $7.78 billion implies an 11% improvement from the year-ago recorded figure.

Factors to Consider for BKRAccording to data from the U.S. Energy Information Administration, average Cushing, OK, WTI spot prices stood at $80.46, $83.90 and $97.31 per barrel in July, August and September 2026, respectively, significantly higher than $68.39, $64.86 and $63.96 per barrel in the corresponding months of 2025.

The substantial year-over-year increase in crude prices, primarily driven by geopolitical tensions surrounding the Iran war, likely created a favorable business environment for Baker Hughes. Stronger commodity prices may have supported upstream spending and demand for oilfield services, potentially benefiting the company's third-quarter earnings and cash flows.

However, the positive impact of elevated oil prices may have been partly offset by disruptions stemming from the Middle East conflict. Project delays, supply-chain challenges and higher operating costs could have affected BKR's operations and weighed on quarterly profitability.

Earnings WhispersOur proven model does not conclusively predict an earnings beat for BKR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is the case here, as you will see below.

Earnings ESP: BKR has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Zacks Rank: BKR currently sports a Zacks Rank #1.

Stocks to ConsiderHere are some energy stocks that you may want to consider, as these have the right combination of elements to post an earnings beat this reporting cycle.

ExxonMobil Holdings Corporation (XOM - Free Report) has an Earnings ESP of +5.37% and currently sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

XOM is scheduled to release third-quarter 2026 earnings on Oct. 30. The Zacks Consensus Estimate for XOM’s earnings is pegged at $3.96 per share, indicating a 110.6% improvement from the prior-year reported figure.

EOG Resources (EOG - Free Report) has an Earnings ESP of +2.43% and carries a Zacks Rank #2 at present. EOG is scheduled to release third-quarter 2026 earnings on Nov. 5.

The Zacks Consensus Estimate for EOG’s earnings is pegged at $4.44 per share, suggesting a 63.4% improvement from the prior-year reported figure.

BP plc (BP - Free Report) has an Earnings ESP of +7.13% and a Zacks Rank #1. BP is scheduled to release third-quarter 2026 earnings on Oct. 30.

The Zacks Consensus Estimate for BP’s earnings is pegged at $2.66 per share, suggesting a 212.9% increase from the prior-year reported figure.

CRISPR Therapeutics AG (CRSP - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Over the past month, shares of this company have returned -10.3%, compared to the Zacks S&P 500 composite's -1.2% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has lost 2.4%. The key question now is: What could be the stock's future direction?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, CRISPR Therapeutics is expected to post a loss of $1.07 per share, indicating a change of +8.6% from the year-ago quarter. The Zacks Consensus Estimate has changed +8.6% over the last 30 days.

The consensus earnings estimate of -$4.48 for the current fiscal year indicates a year-over-year change of +30.8%. This estimate has changed +2.1% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $3.64 indicates a change of +18.7% from what CRISPR Therapeutics is expected to report a year ago. Over the past month, the estimate has changed -5.5%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, CRISPR Therapeutics is rated Zacks Rank #4 (Sell).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of CRISPR Therapeutics, the consensus sales estimate of $9.95 million for the current quarter points to a year-over-year change of +1017.4%. The $32.45 million and $141.72 million estimates for the current and next fiscal years indicate changes of +824.5% and +336.7%, respectively.

Last Reported Results and Surprise HistoryCRISPR Therapeutics reported revenues of $10.18 million in the last reported quarter, representing a year-over-year change of +1043.8%. EPS of -$0.94 for the same period compares with -$1.29 a year ago.

Compared to the Zacks Consensus Estimate of $7.42 million, the reported revenues represent a surprise of +37.28%. The EPS surprise was +14.55%.

Over the last four quarters, CRISPR Therapeutics surpassed consensus EPS estimates two times. The company topped consensus revenue estimates just once over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

CRISPR Therapeutics is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about CRISPR Therapeutics. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.

Key Takeaways CCEP's Southeast Asia revenues climbed 9% in first-half 2026, outpacing company-wide growth of 6.1%.Philippines' EBIT margin nears 10%, while Indonesia's sparkling volumes return to growth.CCEP's new Philippines facility is set to begin production in 2027, supporting regional capacity and demand. Coca-Cola Europacific Partners plc (CCEP - Free Report) is getting a larger share of its growth from Southeast Asia, giving the company an additional expansion lever outside its mature European markets. First-half 2026 results showed faster regional revenue growth, better execution in the Philippines and Indonesia, and continued investment in production capacity.

The opportunity is meaningful, but the region still has to prove it can scale enough to offset slower growth and tougher comparisons elsewhere. CCEP’s execution, route-to-market improvements and planned capacity additions will be central to that test.

Image Source: Zacks Investment Research

CCEP’s Southeast Asia Revenue Gains SpeedSoutheast Asia delivered solid mid-single-digit volume growth in the first half of 2026, while revenues increased 9% on an FX-neutral basis. That pace exceeded the company’s overall comparable FX-neutral revenue growth of 6.1% and highlights the region’s growing importance within CCEP’s geographic mix.

Management has described Southeast Asia as the company’s fastest-growing market area. The combination of population growth, category development and improving commercial execution gives CCEP room to expand beyond its established European base, where affordability pressure and tougher comparisons can limit growth.

CCEP Builds Momentum in the PhilippinesThe Philippines remains an important part of the Southeast Asia story. Coca-Cola Zero Sugar posted double-digit growth in the first half, while Wilkins water benefited from additional listings. Those gains show CCEP broadening demand across both sparkling and hydration categories.

Profitability is also improving. The Philippines’ EBIT margin is approaching CCEP’s 10% target, indicating that the business is making progress not only on revenues but also on operating economics. Better margins would make the market a more meaningful contributor to group profit as volumes scale.

CCEP’s Indonesia Reset Supports RecoveryIndonesia is showing signs of recovery after a weaker 2025 comparison. CCEP said sparkling volumes returned to growth in the first half, supported by products such as Coke Zero Vanilla and Sprite Nipis Mint, while Powerade was also introduced into the market.

A revamped route-to-market model is helping CCEP strengthen execution and improve category participation with distribution partners. That matters because the growth case in Indonesia depends on more than product launches. Wider availability, better outlet execution and stronger distribution can determine whether innovation translates into sustained volume gains.

How CCEP Compares With Bottling PeersThe Southeast Asia push also matters when CCEP is viewed against other Coca-Cola system bottlers. Coca-Cola HBC AG (CCHGY - Free Report) reported 9.6% organic revenue growth and 7.5% volume growth in the first half of 2026, with its Emerging segment posting 12% organic revenue growth. That performance shows how faster-growing geographies can lift the growth profile of a diversified bottler.

Coca-Cola FEMSA, S.A.B. de C.V. (KOF - Free Report) , the world’s largest Coca-Cola franchise bottler by sales volume, reported 1.2% volume growth and 6% comparable revenue growth in the first quarter of 2026. Its scale across Latin America illustrates the value of building dense distribution and broad category participation in developing beverage markets. For CCEP, the Philippines and Indonesia offer a similar strategic opportunity, though the businesses are at different stages and operate in different regions.

CCEP Adds Capacity for Future Regional DemandCCEP is also investing ahead of expected demand. Construction of a new Philippines facility remains on track for production to begin in 2027, adding capacity to support long-term growth. The project sits alongside broader investment in coolers, technology and supply-chain capabilities.

Additional capacity should give CCEP more flexibility as consumption rises and the company expands its portfolio across zero sugar, water, sports and other faster-growing categories. If distribution and profitability continue improving, Southeast Asia could become a progressively larger part of CCEP’s growth algorithm rather than remain a smaller regional contributor.

CCEP’s Ratings Keep Execution Risk in FocusSoutheast Asia strengthens CCEP’s longer-term growth case, but the stock’s current ratings still call for caution. The business faces consumer affordability pressure, rising input and logistics costs and uneven performance across developed markets, while its valuation remains elevated relative to its own history.

CCEP currently carries a Zacks Rank #4 (Sell). The stock has a Growth Score of B, but a Value Score of D, Momentum Score of C and VGM Score of C. The mix supports the view that Southeast Asia is a credible growth catalyst, but investors still need evidence that regional gains can become large enough and profitable enough to outweigh valuation, cost and mature-market risks.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

 | Source: ZENTALIS PHARMACEUTICALS

Median overall survival of 15.9 months in Cyclin E1-positive PROC, with 1–5 prior lines of therapy; safety profile in DENALI Part 1b was consistent with prior reportingMedian relative dose intensity was 84.6%, confirming high overall exposure to azenosertibDENALI Part 1b interim analysis adds to the body of evidence supporting Cyclin E1 protein expression as a predictive biomarker for azenosertib in platinum-resistant ovarian cancer
SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today presented results from an interim analysis of the DENALI Part 1b study (GOG-3066) as of a May 22, 2026 data cutoff, including the first overall survival analysis for azenosertib, at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

"These data continue to build the body of evidence supporting azenosertib as a potential treatment in Cyclin E1-positive platinum-resistant ovarian cancer, underpinning our development approach through the ongoing registration-intended DENALI Part 2 and ASPENOVA Phase 3 confirmatory trials. For patients with Cyclin E1-positive PROC who have limited effective treatment options, we are working to deliver something that has not existed — a targeted, oral treatment that offers more convenience and choice," said Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals.

"The overall survival results from DENALI Part 1b are particularly meaningful given the poor prognosis associated with Cyclin E1-positive tumors and the heavily pretreated nature of this trial patient population," said Fiona Simpkins, M.D., Professor at the University of Pennsylvania Perelman School of Medicine and Lead Investigator for the DENALI study and The GOG Foundation, Inc. (GOG-F). "The separation in median overall survival between Cyclin E1-positive and Cyclin E1-negative patients — 15.9 months versus 7.5 months — strongly supports Cyclin E1 protein expression as a clinically relevant and predictive patient selection biomarker for azenosertib. Taken together with the response data and manageable adverse events, these findings provide important evidence supporting continued development of azenosertib in this biomarker-selected population with high unmet need."

Updated DENALI Part 1b Efficacy Results
As of the May 22, 2026 data cutoff, DENALI Part 1b enrolled 102 patients with PROC regardless of Cyclin E1 protein expression who had received between one and five prior lines of therapy, with prior bevacizumab required. This was a heavily pretreated population: 97% had received a taxane, 91% bevacizumab, 55% a PARP inhibitor, and 15% mirvetuximab soravtansine, with a median of three prior lines of therapy. Cyclin E1 status was retrospectively determined by immunohistochemistry using a proprietary cutoff, with 94 patients evaluable (Cyclin E1 IHC-positive: n=48, 51%; Cyclin E1 IHC-negative: n=46).

Overall Survival (OS):

Cyclin E1 IHC-positive (n=48): median OS of 15.9 months (95% CI, 8.7–21.2); 31 events had occurred (65%)Cyclin E1 IHC-negative (n=46): median OS of 7.5 months (95% CI, 5.8–12.3); 34 events had occurred (74%) Objective Response Rate (ORR) and Duration of Response (DOR):

ORR in response-evaluable Cyclin E1 IHC-positive patients (n=43): 37.2% (95% CI, 23.0–53.3)ORR in all Cyclin E1 IHC-positive patients (n=48): 33.3% (95% CI, 20.4–48.4)Median DOR: 5.5 months (95% CI, 4.5–15.9)
The updated ORR includes a patient with a confirmed response after the prior cutoff. The current median DOR of 5.5 months reflects a more mature dataset with less censoring than the prior cutoff, including two patients with particularly durable responses exceeding 15 and 20 months.

Safety
The safety profile was consistent with prior reporting. The most common treatment-related adverse events (TRAEs) were nausea, fatigue, diarrhea, thrombocytopenia, decreased appetite, anemia, and neutropenia. The most common non-hematologic Grade ≥3 TRAE was fatigue (16%). Grade ≥3 hematologic TRAEs included thrombocytopenia (12%), anemia (11%), and neutropenia (11%).

The median relative dose intensity was 84.6%, confirming that overall exposure to azenosertib remained high despite dose modifications. TRAEs led to dose interruption in 56.9% of patients, dose reduction in 43.1%, and discontinuation in 19.6%. Serious TRAEs occurred in 21.6% of patients.

The ESMO slides inclusive of the full interim analysis dataset presented at the medical meeting are available on the Zentalis website under scientific publications at the following link: https://zentalis.com/science/scientific-publications/

About the DENALI Clinical Trial
DENALI is a multi-part Phase 2 registration-intended clinical trial (NCT05128825, GOG-3066) studying azenosertib in patients with PROC, conducted in collaboration with The GOG Foundation, Inc. (GOG-F).

Part 1b enrolled 102 patients with PROC regardless of Cyclin E1 protein expression, all treated at 400 mg QD 5:2 (five days of once-daily administration of azenosertib, followed by two days without azenosertib). The primary endpoint was objective response rate per RECIST v1.1; secondary endpoints included duration of response, progression-free survival, overall survival, and safety.

Part 2 is prospectively enrolling PROC patients with Cyclin E1 protein overexpression based on Zentalis' proprietary immunohistochemistry cutoff. Part 2, in total, is designed to support accelerated approval, pending positive study outcomes and further discussions with the FDA. The study design consists of the following parts:

Part 2a: Dose confirmation evaluated two doses, 300 mg QD 5:2 and 400 mg QD 5:2, with approximately 30 patients enrolled per dose group. 400 mg QD 5:2 was selected as the optimal monotherapy dose. Recruitment at the 300 mg QD 5:2 dose level has been discontinued. All patients enrolled in Part 2a will contribute to the overall safety database submitted to the FDA.Part 2b: Enrollment expansion at the selected 400 mg QD 5:2 dose up to approximately 100 patients, including patients at this dose in Part 2a. Enrollment in this cohort is complete.Part 2c: Expansion of the study population, expected to enroll approximately 40 patients previously treated with a taxane-containing regimen for PROC. This cohort is currently enrolling.
For physician and patient information about the DENALI trial, please visit www.denalitrial.com.

About ASPENOVA Clinical Trial
ASPENOVA is a Phase 3 randomized, confirmatory clinical trial designed to support full approval of azenosertib in patients with Cyclin E1-positive PROC. The trial is expected to enroll approximately 420 patients and compare azenosertib monotherapy at 400mg QD 5:2 to investigator's choice of standard-of-care single-agent chemotherapy (paclitaxel, pegylated liposomal doxorubicin [PLD], gemcitabine, or topotecan) in this biomarker-selected population. The primary endpoint is progression-free survival (PFS); key secondary endpoints include overall survival (OS) and overall response rate (ORR). The trial design was based on feedback from the U.S. FDA regarding requirements for seeking approval under the accelerated approval pathway and requirements to support potential conversion to full approval.

About Azenosertib
Azenosertib is an investigational, potentially first-in-class, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated in clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage and leading to mitotic catastrophe and cancer cell death.

Azenosertib is in late-stage development as a potential treatment for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). There is currently no approved treatment option specifically for this biomarker-selected population which comprises approximately 50% of PROC patients. Cyclin E1 protein overexpression has been established as a sensitive and specific predictive biomarker for identifying patients who could potentially derive benefit from azenosertib treatment.

About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.​

For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the continued development of azenosertib; the clinical and therapeutic potential of azenosertib; the potential for azenosertib to be first-in-class; the broad franchise potential of azenosertib; the Company’s biomarker-driven strategy for azenosertib, including the ability of Cyclin E1 to be a highly selective and predictive biomarker for response to azenosertib; and our participation in conference presentations. The terms “anticipate,” “advance,” “believe,” “design,” “develop,” “expect,” “intent,” “look forward,” “on track,” “plan,” “position,” “potential,” “runway,” “strategy,” “support,” “target,” “upcoming,” and “will” and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of azenosertib; our plans, including the costs thereof, of development of companion diagnostics; the outcome of preclinical testing and early trials may not be predictive of the success of later clinical trials; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel, and risks relating to management transitions; significant costs as a result of operating as a public company; and the other important factors discussed under the caption “Risk Factors” in our most recently filed periodic report on Form 10-K or 10-Q and subsequent filings with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release. 

Contact: 
Aron Feingold
VP, Investor Relations & Corporate Communications
[email protected]